Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Since intangibles such as goodwill cannot be sold when the company liquidates, tangible book value per share is considered more accurate in reflecting how much shareholders will receive when the company liquidates.
Sagimet Biosciences (STU:0O2) Tangible Book per Share Explanation
Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.
For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.
Sagimet Biosciences Tangible Book per Share Related Terms
Sagimet Biosciences Tangible Book per Share Historical Data
* Premium members only.
The historical data trend for Sagimet Biosciences's Tangible Book per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:0O2 vs EDIT, AUTL, FBRX: Tangible Book per Share Comparison
For the Biotechnology subindustry, Sagimet Biosciences's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sagimet Biosciences Price-to-Tangible-Book vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sagimet Biosciences's Price-to-Tangible-Book distribution charts can be found below:
* The bar in red indicates where Sagimet Biosciences's Price-to-Tangible-Book falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Theoretically it is what the shareholders will receive if the company is liquidated. Total equity is a balance sheet item and equal to total assets less total liabilities of the company. Since intangibles such as goodwill cannot be sold when the company liquidates, tangible book value per share is considered more accurate in reflecting how much shareholders will receive when the company liquidates.
What does a Tangible Book per Share of €2.72 mean?
Sagimet Biosciences (STU:0O2) has a Tangible Book per Share of €2.72 as of Mar. 2026. Tangible book per share equals the per-share value of a company's tangible equity. View historical data on Sagimet Biosciences and its competitors.
Is Sagimet Biosciences' Tangible Book per Share too high?
Sagimet Biosciences' current Tangible Book per Share is €2.72. Overall, Sagimet Biosciences has a GF Score™ of 38/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sagimet Biosciences' Tangible Book per Share compare to EDIT and AUTL?
Sagimet Biosciences' Tangible Book per Share of €2.72 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tangible Book per Share for a Biotechnology company?
A good Tangible Book per Share depends on the Biotechnology industry context. However, Tangible Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tangible Book per Share mean?
A high Tangible Book per Share can signal that a stock is expensive relative to its fundamentals. Tangible book per share equals the per-share value of a company's tangible equity. View historical data on Sagimet Biosciences and its competitors. Sagimet Biosciences's current Tangible Book per Share is €2.72. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sagimet Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Sagimet Biosciences (STU:0O2) is currently considered Modestly Overvalued. The stock's GF Value™ is €5.69, compared to a current price of €6.40 — trading 12.5% above its estimated fair value. The current Tangible Book per Share is €2.72. Sagimet Biosciences' overall GF Score™ is 38/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tangible Book per Share calculated?
Tangible Book per Share is calculated from a company's financial statements. For Sagimet Biosciences (STU:0O2), the current Tangible Book per Share is €2.72 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sagimet Biosciences (STU:0O2) Overvalued in 2026?
Based on GuruFocus' analysis, Sagimet Biosciences stock appears to be overvalued.
The current stock price of €6.40 is trading 12.5% above its estimated GF Value™ of €5.69.
GuruFocus considers Sagimet Biosciences to be Modestly Overvalued.
Key valuation signals for STU:0O2:
Tangible Book per Share: €2.72
GF Value™: €5.69 vs. price of €6.40 (12.5% above fair value)
No single metric tells the full story. See the STU:0O2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sagimet Biosciences Inc a clinical-stage biopharmaceutical company developing novel therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Its drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), acne and select forms of cancer. Its second FASN inhibitor, TVB-3567, is a potent and selective small molecule FASN inhibitor in development for acne. It operates as a single business segment, developing and commercializing therapeutics for the treatment of MASH and other diseases where FASN plays a pathogenic role.
38GF Score
Get the complete analysis for STU:0O2
Tangible Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:0O2 has been successfully added to your 
